Unlike the surgical method, Hera’s test (MetriDxTM) is capable of diagnosing and staging endo, quantitatively. This capability provides physicians objective data, which can be used in the clinical management of the disease. Collecting patient tissue samples is a common practice in physician offices. The uterine tissue sample required for Hera’s test will be collected via a Pipelle biopsy and shipped to Hera’s lab for analysis. This entire process is well-established as it is comparable to the model used for a PAP smear. MetriDxTM will greatly reduce wait time and failure rates associated with the current standard by moving diagnostic capability from the OR to the physician’s office, eliminating both guesswork and patient downtime from the equation.
Company Profile Link - https://www.startupsteroid.com/founder?founderUserId=BD17F432-E80A-4FD5-BD91-6DF7A8C3C12D